Tag: targeted therapy
KRAS-G12D inhibitor shows promise in advanced pancreatic cancer: phase 1b/2 trial results
A phase 1b/2 trial published in Nature Medicine demonstrates that HRS-4642, a targeted KRAS-G12D inhibitor combined with chemotherapy, achieves encouraging…
New molecular mechanism in inherited heart disease offers pathway for targeted therapy
Researchers at Spain's CNIC have identified a shared molecular mechanism in hypertrophic cardiomyopathy that operates across multiple genetic mutations, opening…
Targeted therapy combined with chemotherapy shows promise in advanced pancreatic cancer
An investigational targeted therapy combined with standard chemotherapy has shown promising early efficacy in advanced pancreatic cancer, according to data…
Rb Pathway Inactivation Drives Squamous Transformation in EGFR-Mutant Lung Cancers
A clinicogenomic analysis published in Science Translational Medicine reveals that retinoblastoma pathway inactivation drives squamous transformation in EGFR-mutant lung adenocarcinomas,…
New Drug Shows Promise for Rare Gastrointestinal Tumors in Phase 2 Trial
A phase 2 trial shows rogaratinib, an FGFR inhibitor, demonstrates encouraging efficacy in patients with SDH-deficient GIST. The study represents…
NHS Approves First New Ovarian Cancer Drug in 20 Years for Resistant Disease
NHS approves mirvetuximab soravtansine, the first new ovarian cancer treatment in over 20 years for women with platinum-resistant disease. The…
Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival
New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly doubling survival times. Clinical trial shows 60% reduction…
Breakthrough Drug Shows 75% Response Rate in Hard-to-Treat Lung Cancer
Sunvozertinib achieved a 75% response rate in previously untreated lung cancer patients with EGFR exon 20 mutations, compared to 25%…